Eupraxia Pharmaceuticals Inc.
corporate_fare Company Profile
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) is a publicly traded company in the Life Sciences sector. Wiseek monitors EPRX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Eupraxia Reshapes Executive Team Ahead of Pivotal EoE Data Readout
- Eupraxia Adds Three Pharma Veterans to Board, Bolstering Commercialization Expertise
- Eupraxia Pharmaceuticals Reports Strong Histological Improvements in EoE Trial
- Eupraxia Pharmaceuticals Reports Strong EREFS Data for EP-104GI in EoE RESOLVE Trial
- Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for EPRX, detected from its recent SEC filings · based on capital-structure filings through 2026-02-19.
Formalizes Public Offering Terms · Capital Raise Details Confirmed
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
EPRX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.